CRISPR, AI, and Personalized Approaches Shape the Future of Pediatric Gene Therapy

The future of pediatric gene therapy is being reshaped by a three-way convergence: CRISPR–Cas9 genome editing, artificial intelligence (AI), and personalized medicine. Together, these approaches are opening routes toward durable, potentially curative treatments for rare genetic disorders that have historically had limited options for children.

CRISPR–Cas9 remains at the center of this transformation by enabling sequence-specific correction of disease-causing mutations. In principle, carefully designed guide RNAs can target pathogenic alleles while minimizing off-target activity, supporting both ex vivo and in vivo strategies. Early momentum is especially strong in hematological diseases, where patient cells can be edited and reinfused under controlled conditions.

AI is accelerating the translation pipeline by improving how researchers choose targets, evaluate guide performance, and plan experiments. Models such as DeepCRISPR and CRISPR-GPT are being used to predict editing outcomes, prioritize candidate edits, and refine experimental designs before costly laboratory work. This can shorten cycles from concept to preclinical validation.

Personalized medicine adds a crucial layer: therapy design increasingly accounts for each child’s genetic background, developmental context, and the heterogeneity of disease mechanisms. Rather than relying on one-size-fits-all constructs, researchers are moving toward patient-specific decision-making, including tailoring edits to relevant variants.

Delivery technology is also expanding what is practically achievable in pediatric settings. Adeno-associated virus (AAV) vectors remain a leading tool for transporting CRISPR components, while non-viral platforms such as lipid nanoparticles (LNPs) are gaining traction due to their scalable formulation and potentially different safety and targeting profiles.

The combined system—editing, AI-guided selection, and customized clinical targeting—aims to improve both efficacy and safety. In practice, this requires rigorous characterization of editing efficiency, durability of correction, and immune or inflammatory responses triggered by vectors or components.

Because pediatric therapy raises distinct ethical and regulatory concerns, progress depends on transparent risk assessment and consensus frameworks for evaluating both gene-editing biology and AI-driven decision support. Standardized regulatory pathways will be essential to ensure therapies are safe, equitable, and scalable beyond early trials.

Pan, Ding, Wang and colleagues highlight that interdisciplinary collaboration across genome engineering, AI science, pediatric clinical care, bioethics, and policy will determine whether these innovations reach children effectively and responsibly.